CERAMED is building a precision psychiatry solution for major depression care.

Depression remains the last major medical field without biological guidance. 50% of patients don't respond to first-line antidepressants. Clinicians lack biomarkers. Result: months or even years of trial-and-error during peak complication risk.

Our solution: CeraDOSE® – an affordable blood test paired with ML interpretation models, enabling biomarker-informed clinical precision. Think HbA1c for diabetes, upgraded: not just a biomarker, but a cloud-based intelligence layer enabling biomarker-informed clinical precision. 

Our science relies on patented sphingolipidic biomarkers analyzed via LC-MS/MS and proprietary Model Factory algorithms. Foundational paper under peer review, performance results publication expected in 2026.

Partnerships: AP-HP, UK Erlangen, FU Berlin and leading diagnosis players across 3 continents (announcements in 2026). CE-IVD target: late 2027 / early 2028 | FDA pathway in preparation.

CERAMED

Org chart

Teams

Offices

CERAMED

Org chart

Teams

Offices

Related companies